Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. The submission qualifies for the NMPA’s “green channel” pathway, an expedited review process designed for innovative medical technologies addressing significant clinical needs. This designation is expected to streamline the approval timeline and facilitate faster entry into the Chinese market.
China represents a substantial opportunity in cardiology, with cardiovascular disease as the leading cause of mortality and an estimated 330 million patients affected. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness and scalability, but variability in image interpretation and limited access to MRI have created demand for AI-driven tools. Ventripoint’s VMS+™ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography, powered by the company’s proprietary Knowledge Based Reconstruction technology. The platform enables assessment of all four heart chambers, supporting diagnosis of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption.” Hugh MacNaught, President and CEO of Ventripoint Diagnostics, added, “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly.”
Ventripoint’s VMS+™ products are powered by proprietary Knowledge Based Reconstruction technology, providing accurate volumetric cardiac measurements equivalent to MRI. The system is compatible with all ultrasound systems from any vendor supported by regulatory approvals in the U.S., Europe, and Canada. Lishman Global, established in 2012, assists foreign companies in navigating regulatory approvals and distribution channels in the Chinese medical device market. For more information, visit the original release on NewMediaWire.
The company will provide further updates as the regulatory review progresses. This submission marks a key milestone in Ventripoint’s global expansion strategy, reflecting growing demand for advanced cardiac imaging solutions in one of the world’s largest healthcare markets.
